Unknown

Dataset Information

Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.


ABSTRACT:

Importance

Outcome data are limited regarding early experience with brolucizumab, the most recently approved anti-vascular endothelial growth factor (VEGF) agent for the treatment of neovascular age-related macular degeneration (nAMD).

Objective

To report clinical outcomes after intravitreous injection (IVI) of brolucizumab, 6 mg, for nAMD.

Design, setting, and participants

This retrospective case series conducted at 15 private or academic ophthalmological centers in the United States included all consecutive patients with eyes treated with brolucizumab by 6 retina specialists between October 17, 2019, and April 1, 2020.

Exposures

Treatment with brolucizumab IVI, 6 mg.

Main outcomes and measures

Change in mean visual acuity (VA) and optical coherence tom

SUBMITTER: Enriquez AB 

PROVIDER: S-EPMC7907988 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature